130464-55-0

Usage

Uses

Used in Pharmaceutical Industry:
Peucedanocoumarin I is used as an antifungal agent for its ability to combat fungal infections, providing a natural alternative to synthetic antifungal drugs.
Used in Oncology:
In the field of oncology, Peucedanocoumarin I is utilized as an anticancer agent, targeting various types of cancer cells and potentially enhancing the effectiveness of conventional cancer treatments.
Used in Inflammation Management:
Peucedanocoumarin I is employed as an anti-inflammatory agent, leveraging its properties to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Used in Antiviral Research:
As an antiviral agent, Peucedanocoumarin I is being investigated for its potential to inhibit viral replication and activity, offering a new avenue for the development of antiviral therapies.
These applications highlight the diverse therapeutic potential of Peucedanocoumarin I, which is currently under active research to further explore its benefits and optimize its use in medical treatments.

Upstream product

• 116-53-0 2-Methylbutanoic acid 
• 4955-21-9 (+/-)-cis-4'-acetylkhellactone 

Downstream Products

• 518-76-3 (+)-(3'S,4'R)-trans-khellactone 
• 54712-23-1 (-)-cis-(3'S,4'S)-khellactone 

Relevant academic research and scientific papers

The antagonistic effects of khellactones on platelet-activating factor, histamine, and leukotriene D4

Khellactones of Peucedanum praeruptorum Duun., including praeruptorins A (= Pd-Ia, 2) and B (= Pd-II, 11), had an antagonistic effect specifically on platelet aggregation induced by platelet activating factor (PAF) among various aggregating agents examined, and represent a new class of PAF antagonists. We examined the effects of twenty compounds on PAF-induced platelet aggregation and on histamine- and leukotriene D4 (LTD4)-induced contractions in isolated guinea pig ileum. Compounds 2, (±)-cis-3',4'-diacetylkhellactone (3), (±)-cis-4'-acetyl-3'-crotonoylkhellactone (5), (±)-cis-4'-acetyl-3'-tetrolylkhellactone (6), (±)-cis-4'-acetyl-3'-tigloylkhellactone (7), (±)-cis-4'-acetyl-3'-(2''-methylbutyryl)khellactone (8), (±)-cis-3',4'-ditigloylkhellactone (10), and 11 all strongly inhibited PAF-induced platelet aggregation. (±)-cis-4'-Acetyl-3'-(2''-methyl-2''-dodecenoyl)khellactone (9), (±)-cis-4'-ethyl-3'-tigloylkhellactone (13), (±)-cis-4'-ethyl-3'-[N-(2''-triethylammonio)ethylcarbamoyl]khellacton e iodide (16), (±)-trans-3',4'-diacetylkhellactone (18), (±)-trans-4'-acetyl-3'-crotonoylkhellactone (19), (±)-trans-4'acetyl-3'-valerylkhellactone (20), (±)-trans-4'-acetyl-3'-isovalerylkhellactone (21), and (±)-trans-4'-acetyl-3'-tigloylkhellactone (22) were weakly inhibitory. Most of the compounds exhibited noncompetitive antagonist actions on histamine- and LTD4-induced contractions. The potencies of the antagonistic effects on histamine action were in the order 7 = 22 ≥ 2 = 8 = 10 > 6 = 11 = 13 ≥ 5 > 19 = 9 and those on LTD4 action were in the order 6 = 22 = 2 > 10 = 8 > 7 = 9 = 11 ≥ 13. Thus, compounds with potent PAF-antagonistic activities have the following features: cis isomers of khellactone at the C-3' and C-4' positions are more favorable than trans isomers, and the acyl moiety at the C-3' position of khellactone must be of an appropriate molecular size. In the case of histamine- and LTD4-antagonistic activities, both isomers show similar effects and acyl moieties of appropriate size are required at the C-3' and C-4' positions. These results are of interest in regard to the medicinal uses of Peucedanum species as a herbal drug.